Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress in the mechanism and drug development of castration-resistant prostate cancer.

Future medicinal chemistry - 1 May 2016

Zuo Minzan, Xu Xi, Li Tinghan, Ge Raoling, Li Zhiyu

Abstract excerpt

Although prostate cancer can initially respond to androgen deprivation therapy, it will inevitably relapse and switch to a castration-resistant state. The progress in understanding the mechanism of castration-resistant prostate cancer (CRPC) has led to the evolution of novel agents, including sipuleucel-T as an immunomodulant agent, enzalutamide as an androgen receptor antagonist, docetaxel as a chemotherapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Angiogenesis Inhibitors
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Immunologic Factors

Share to Prostatic Neoplasms, Castration-Resistant

Share to Radiopharmaceuticals

Share to Testosterone

Source

Identifiers

PMID: 27149562
DOI: 10.4155/fmc.16.12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress in the mechanism and drug development of castration-resistant prostate cancer.PMID 27149562Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate CancerSemantic proximity Read ↗

[The concept and mechanisms of castration-resistant prostate cancer].Semantic proximity Read ↗

Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.Semantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glanceSemantic proximity Read ↗

Development and prevalence of castration-resistant prostate cancer subtypesSemantic proximity Read ↗

Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.Semantic proximity Read ↗

Molecular pathogenesis and progression of prostate cancer.Semantic proximity Read ↗

Therapy escape mechanisms in the malignant prostate.Semantic proximity Read ↗

[Recent trend in the development of novel treatments based on the mechanisms of prostate cancer progression].Semantic proximity Read ↗

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.